Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).


Journal Article

The utility of glycoprotein IIb/IIIa receptor inhibitors as a "bail-out" modality after unsuccessful primary percutaneous coronary intervention for acute myocardial infarction is unknown. In the CADILLAC trial, of 1,030 control patients, 62 patients (6.0%) crossed over and received abciximab for procedural complications or suboptimal angioplasty results. Compared with patients who received routine upfront abciximab, those treated with bail-out abciximab had markedly lower rates of Thrombolysis In Myocardial Infarction grade 3 flow and increased rates of hemorrhagic and ischemic complications at 30 days and 1 year.

Full Text

Duke Authors

Cited Authors

  • Ashby, DT; Aymong, EA; Tcheng, JE; Grines, CL; Cox, DA; Mehran, R; Garcia, E; Griffin, JJ; Guagliumi, G; Stuckey, T; Turco, M; Lansky, AJ; Stone, GW; CADILLAC Trial,

Published Date

  • November 1, 2003

Published In

Volume / Issue

  • 92 / 9

Start / End Page

  • 1091 - 1094

PubMed ID

  • 14583362

Pubmed Central ID

  • 14583362

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/j.amjcard.2003.06.005


  • eng

Conference Location

  • United States